Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype

Next Previous
Trial Profile

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Depemokimab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms SWIFT-2
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

Most Recent Events

  • 26 May 2025 According to GSK media release,results from this trial have been reported and published in the New England Journal of Medicine.
  • 26 May 2025 According to GSK media release, company announced that it has submitted a New Drug Submission (NDS) to Health Canada for depemokimab.The NDS is based on data from the positive SWIFT and ANCHOR trials.
  • 28 Jan 2025 According to GSK media release, company announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications based on SWIFT and ANCHOR trials

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top